Abstract
Purpose :
Acute posterior multifocal placoid pigment epitheliopathy (APMPPE), ampiginous choroiditis, and serpiginous choroiditis are rare posterior uveitic diseases that cause choroidal and outer retinal inflammation, and associated with choriocapillaris nonperfusion. Little is known of the longitudinal course of atrophy in these diseases.
Methods :
A retrospective chart review of 17 patients between 1/2010 and 10/2023 with placoid-spectrum disease was performed. Demographic data, visual acuity, diagnosis, immunosuppressive therapies, and recurrences were evaluated. Color fundus photographs, optical coherence tomography (OCT), and fundus autofluorescence were evaluated.
Results :
Patients were diagnosed with APMPPE (5, 29.4%), ampiginous choroiditis (7, 41.1%), and serpiginous choroiditis (5, 29.4%). Mean visual acuity on presentation for APMPPE and serpiginous choroiditis with Snellen 20/40, while in ampiginous choroiditis was 20/30. On last follow up, mean visual acuity was 20/20 for APMPPE, 20/30 in ampiginous choroiditis, and 20/35 in serpiginous choroiditis. Chorioretinal atrophy was seen in (20%, 1/5) APMPPE, (71.4%, 5/7) in ampiginous choroiditis, and (100%, 5/5) in serpiginous choroiditis. The atrophy progressed in all patients regardless of refractive status. Chorioretinal atrophy progressed into the fovea causing vision loss in 1 ampiginous patient who otherwise was quiescent on immunosuppressive therapy.
Conclusions :
Patients with placoid spectrum disease have progressive chorioretinal atrophy, even after achieving disease quiescence with immunosuppressive therapy. Progressive atrophy may cause permanent central vision loss.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.